Exposure to environmental chemicals is a risk factor for Parkinson's Disease (PD). Specifically, pesticides used in agriculture, such as the organochlorine dieldrin, are associated with PD incidence;however, the link between exposure and disease is not known, and the underlying mechanisms remain to be determined. A potential pathway involves oxidative stress. Dieldrin, which is associated with PD incidence, has been shown to induce this injurious condition. However, it is not known how general oxidative stress, resulting from environmental exposure, can translate into specific dopaminergic toxicity. A proposed mechanism to account for this involves 3,4-dihydroxyphenylacetaldehyde (DOPAL), a dopamine (DA) derived neurotoxin. DA is metabolized to the toxic intermediate, DOPAL, which is oxidized via mitochondrial aldehyde dehydrogenase (mALDH) to 3,4-dihydroxyphenyl acetic acid (DOPAC) using the cofactor NAD. Aldehydes generated via oxidative stress, e.g., 4-hydroxynonenal (4HNE), are potent inhibitors of mALDH;therefore, cellular stress resulting from environmental agents may inhibit DOPAL metabolism yielding high levels of the DA-derived aldehyde. Furthermore, impairment of complex I, responsible for generation of mitochondrial NAD, has been observed for pesticides, and such an insult would also decrease the ability of mALDH to metabolize DOPAL. Preliminary data presented in this application demonstrate that both the oxidative stress product 4HNE and dieldrin yield inhibition of mitochondrial metabolism of DOPAL;furthermore, the DA-derived aldehyde is highly reactive toward proteins. Based on previous studies and preliminary data presented in this application, it is hypothesized that the organochlorine dieldrin inhibits cellular metabolism of DOPAL, yielding aberrant levels of this endogenous aldehyde neurotoxin and subsequent protein modification. To test the hypothesis, three specific aims will be completed.
Specific Aim 1 will examine the ability of dieldrin to impair DOPAL metabolism in dopaminergic cells and elucidate the mechanism of inhibition.
Specific Aim 2 will demonstrate protein adduction by the DA-derived aldehyde in cells treated with dieldrin.
Specific Aim 3 will determine the extent of protein modification by DOPAL in vivo in a mouse model of chronic dieldrin dosing. The work proposed in this application is significant and innovative and will serve as a foundation for future research aimed at determining the role of environmetal exposure in PD pathogenesis.
|Vanle, Brigitte C; Florang, Virginia R; Murry, Daryl J et al. (2017) Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. Biochem Biophys Res Commun 492:275-281|
|Anderson, David G; Florang, Virginia R; Schamp, Josephine H et al. (2016) Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite. Chem Res Toxicol 29:1098-107|
|Doorn, Jonathan A; Florang, Virginia R; Schamp, Josephine H et al. (2014) Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons. Parkinsonism Relat Disord 20 Suppl 1:S73-5|
|Vermeer, Lydia M; Higgins, Colin A; Roman, David L et al. (2013) Real-time monitoring of tyrosine hydroxylase activity using a plate reader assay. Anal Biochem 432:11-5|
|Allen, Erin M G; Florang, Virginia R; Davenport, Laurie L et al. (2013) Cellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cells. Chem Res Toxicol 26:1043-54|
|Higgins, Colin A; Vermeer, Lydia M; Doorn, Jonathan A et al. (2012) Expression and purification of recombinant human tyrosine hydroxylase as a fusion protein in Escherichia coli. Protein Expr Purif 84:219-23|
|Vermeer, Lydia M M; Florang, Virginia R; Doorn, Jonathan A (2012) Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity. Brain Res 1474:100-9|
|Jinsmaa, Yunden; Florang, Virginia R; Rees, Jennifer N et al. (2011) Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. Chem Biol Interact 192:118-21|
|Mexas, Lydia M; Florang, Virginia R; Doorn, Jonathan A (2011) Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology 32:471-7|
|Anderson, David G; Mariappan, S V Santhana; Buettner, Garry R et al. (2011) Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J Biol Chem 286:26978-86|
Showing the most recent 10 out of 14 publications